MicroRNA-221 silencing predisposed human bladder cancer cells to undergo apoptosis induced by TRAIL

作者: Qiang Lu , Chao Lu , Guo-Ping Zhou , Wei Zhang , Hang Xiao

DOI: 10.1016/J.UROLONC.2009.06.005

关键词: Tumor necrosis factor alphaCancer cellCancer researchMedicineBladder cancerGene silencingProgrammed cell deathmicroRNACancerImmunologyCell cycle phaseUrologyOncology

摘要: Abstract Objectives Bladder cancer is the most common type of urologic in Chinese males. The 5-year survival rate advanced bladder approximately 20%–40%. There an obvious urgent need for novel and effective therapies against cancer. MicroRNAs (miRNAs) are a recently discovered class noncoding RNAs; suppressing miRNA-221 might prove beneficial several cancers. To explore cancer, we explored effects silencing on cells. Materials methods Northern blot analysis was used to determine expression levels T24 cells, RT4 cells human normal urothelial silenced with antisense oligonucleotides pro-apoptotic effect necrosis factor related apoptosis-inducing ligand (TRAIL) miRNA-221-silenced assessed flow cytometry. p27kip1 protein exposed TRAIL detected by Western blotting. role cell cycle phase distribution investigated through cytometric analysis. Results Human significantly up-regulated compared TRAIL-resistant line. MiRNA-221 predisposed undergo apoptosis induced resulted up-modulation cyclin-dependent kinase inhibitor p27Kip1. suppression promoted activation caspase 3 Conclusions rendered TRAIL. Our findings suggest potential therapy.

参考文章(34)
Nalan Nese, Ruta Gupta, Matthew H. T. Bui, Mahul B. Amin, Carcinoma in situ of the urinary bladder: review of clinicopathologic characteristics with an emphasis on aspects related to molecular diagnostic techniques and prognosis. Journal of The National Comprehensive Cancer Network. ,vol. 7, pp. 48- 57 ,(2009) , 10.6004/JNCCN.2009.0004
Martin L. Brown, Gerald F. Riley, Nicki Schussler, Ruth Etzioni, Estimating health care costs related to cancer treatment from SEER-Medicare data. Medical Care. ,vol. 40, ,(2002) , 10.1097/00005650-200208001-00014
Paul B.J. Burton, Christopher J. Anderson, Cathy M. Corbishly, Caspase 3 and p27 as predictors of invasive bladder cancer. The New England Journal of Medicine. ,vol. 343, pp. 1418- 1420 ,(2000) , 10.1056/NEJM200011093431915
Bo Sun, Jacob A. Moibi, Allan Mak, Zhengwen Xiao, Wilson Roa, Ronald B. Moore, Response of Bladder Carcinoma Cells to TRAIL and Antisense Oligonucleotide, Bcl-2 or Clusterin Treatments Journal of Urology. ,vol. 181, pp. 1361- 1371 ,(2009) , 10.1016/J.JURO.2008.10.148
Clay CC Wang, Yi-Ming Chiang, Po-Lin Kuo, Jiunn-Kae Chang, Ya-Ling Hsu, Norsolorinic acid inhibits proliferation of T24 human bladder cancer cells by arresting the cell cycle at the G0/G1 phase and inducing a Fas/membrane-bound Fas ligand-mediated apoptotic pathway. Clinical and Experimental Pharmacology and Physiology. ,vol. 35, pp. 1301- 1308 ,(2008) , 10.1111/J.1440-1681.2008.05007.X
Michael S. Cookson, Harry W. Herr, Zuo-Feng Zhang, Scott Soloway, Pramod C. Sogani, William R. Fair, The Treated Natural History of High Risk Superficial Bladder Cancer: 15-year Outcome The Journal of Urology. ,vol. 158, pp. 62- 67 ,(1997) , 10.1097/00005392-199707000-00017
J. Vervoorts, B. Lüscher, Post-translational regulation of the tumor suppressor p27(KIP1). Cellular and Molecular Life Sciences. ,vol. 65, pp. 3255- 3264 ,(2008) , 10.1007/S00018-008-8296-7
Alonso Alvarez, Vinata B Lokeshwar, Bladder cancer biomarkers: current developments and future implementation. Current Opinion in Urology. ,vol. 17, pp. 341- 346 ,(2007) , 10.1097/MOU.0B013E3282C8C72B
Mark P. Simons, William M. Nauseef, Thomas S. Griffith, Neutrophils and TRAIL: insights into BCG immunotherapy for bladder cancer. Immunologic Research. ,vol. 39, pp. 79- 93 ,(2007) , 10.1007/S12026-007-0084-1